Filtration leukocytapheresis therapy in the treatment of rheumatoid arthritis patients resistant to or failed with methotrexate

Therapeutic Apheresis and Dialysis

Volumn 8, Issue 3, 2004, Pages 197-205

  Kempe, Kazuo ^a   Tsuda, Hiroshi ^a   Yang, Kwangseok ^a   Yamaji, Ken ^a   Kanai, Yoshinori ^a   Hashimoto, Hiroshi ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ACR core set; Leukocytapheresis; Leukocyte; Methotrexate; Rheumatoid arthritis

Indexed keywords

CD11B ANTIGEN; CD18 ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE;

ADULT; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONFERENCE PAPER; CYTAPHERESIS; FEMALE; FILTRATION LEUKOCYTAPHERESIS; GRANULOCYTE; HUMAN; LEUKOCYTE; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD1; ANTIGENS, CD11A; ANTIGENS, CD11B; ANTIGENS, CD18; ANTIMETABOLITES, ANTINEOPLASTIC; ARTHRITIS, RHEUMATOID; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKAPHERESIS; LEUKOCYTES; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 3142615818     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-0968.2004.00132.x     Document Type: Conference Paper

References (22)

1. Tsuda H. Apheresis for rheumatic disease. Ryumachika 2002;28:107-10.
2. Paulus HE, Mahleder HI, Levine S, Yu DTU, MacDonald NS. Lymphocyte involvement in rheumatoid arthritis: studies during thoracic duct drainage. Arthritis Rheum 1977;20:1249-62.
3. Karsh J, Wright DG, Klippel JH, Decker JL, Deisseroth AB, Wayne Flye M. Lymphocyte depletion by continuous flow cell centrifugation in rheumatoid arthritis: clinical effects. Arthritis Rheum 1979;22:1055-9.
4. Hashimoto H, Tsuda H, Yokoyama M et al. Lymphocytapheresis as a treatment for the patients with systemic lupus erythematosus. Rhinsho Ketueki 1985;26:1892-7.
5. Yamaji K, Yang K, Tsuda H, Hashimoto H. Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers. Ther Apher 2002;6:402-12.
6. Fujita S. Lymphocytapheresis using leukocyte removal filter in rheumatoid arthritis. Jpn J Clin Immun 1990;13:268-76.
7. Kawanishi T, Tsuda H. Therapeutic lymphocytapheresis in rheumatoid arthritis: comparison of leukocyte removal filter methods and centrifugal method. Jpn J Artif Organs 1994;23:506-10.
8. Hidaka T, Suzuki K, Matsuki Y et al. Changes in CD4+T lymphocyte subsets in circulating blood and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. Ther Apher 1999;3:178-85.
9. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
10. Ziebland S, Fitzpatrick R, Jenkinson C, Mowat A. Comparison of two approaches to measuring change in health status in rheumatoid arthritis: the Health Assessment Questionnaire (HAQ) and modified HAQ Ann Rheum Dis 1992;51:1202-5.
11. Felson DT, Anderson JJ, Lange MLM et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
12. Ueki Y, Yamasaki Y, Kanamoto T et al. Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis. Rheumatology 2000;39:165-71.
13. Hidaka T, Suzuki K, Matsuki Y et al. Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:431-7.
14. Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): Analyses in 2941 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol 2001;28:982-9.
15. Tsuda H, Miyakata S, Matsuda Y et al. Apheresis for rheumatoid arthritis. Jpn J Apheresis 1998;17:173-5.
16. Yamasaki S, Ueki Y, Nakamura H et al. Effect of filtration leukocytapheresis therapy: Modulation of white blood cell enzyme activities in patients with rheumatoid arthritis. Artif Organs 2002;26:378-84.
17. Edwards SW, Hallett MB. Seeing the wood for the trees: The forgotten role of neutrophils in rheumatoid arthritis. Immunol Today 1997;18:320-4.
18. Greenwald RA. Oxygen radical, inflammation, and arthritis: Pathophysiological considerations and implications for treatment. Semin Arthritis Rheum 1991;20:219-40.
19. Shappell SB, Toman C, Anderson DC, Taylor AA, Entman ML, Smith CW. Mac-1 (CD11b/CD18) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils. J Immunol 1990;144:2702-11.
20. Smith CW, Marlin SD, Rothlein R, Toman C, Anderson DC. Cooperative interaction of LFA-1 and MAC-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J Clin Invest 1989;83:2008-17.
21. Ribbens C, Andre B, Jasper JM et al. Matrix metalloprotease-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumtaol 2000;27:889-93.
22. Suzuki Y. Methotrexate for the treatment of rheumatoid arthritis in Japan-Much more still remains to be resolved. Nippon Rinsho 2002;60:2331-7.